Peptilogics
Sarah McMichael is an experienced professional in the biopharmaceutical industry, currently serving as Manager of CMC Development at Peptilogics since January 2022. Previously held positions include Manager of MSAT at Sigilon Therapeutics, Inc., and Supervisor of Aseptic Manufacturing at Iovance Biotherapeutics, Inc. At Charles River Laboratories, Sarah worked as a Supervisor and Team Leader, overseeing a team in developing procedures for mammalian cell banks and vaccines. Early career roles include Business Process Manager at Heraeus and various positions during academic years at Juniata College, including facilities and sales roles. Sarah earned a Bachelor of Science in Biology from Juniata College, where notable achievements include being part of the NCAA DIII National Runner-up volleyball team.
This person is not in any offices
Peptilogics
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.